WO2001062799A3 - Method for inhibiting angiogenesis using molecules that enhance plasmin activity - Google Patents

Method for inhibiting angiogenesis using molecules that enhance plasmin activity Download PDF

Info

Publication number
WO2001062799A3
WO2001062799A3 PCT/NL2001/000155 NL0100155W WO0162799A3 WO 2001062799 A3 WO2001062799 A3 WO 2001062799A3 NL 0100155 W NL0100155 W NL 0100155W WO 0162799 A3 WO0162799 A3 WO 0162799A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteinaceous molecule
provides
amyloid
angiogenesis
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2001/000155
Other languages
French (fr)
Other versions
WO2001062799A2 (en
Inventor
Martijn Frans Ben Gera Gebbink
Emile Eugene Voest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitair Medisch Centrum Utrecht
Universiteit Utrecht
Original Assignee
Rijksuniversiteit Utrecht
Universitair Medisch Centrum Utrecht
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rijksuniversiteit Utrecht, Universitair Medisch Centrum Utrecht filed Critical Rijksuniversiteit Utrecht
Priority to EP01912573A priority Critical patent/EP1257582B1/en
Priority to CA002400823A priority patent/CA2400823A1/en
Priority to DE60138524T priority patent/DE60138524D1/en
Priority to AU41262/01A priority patent/AU4126201A/en
Priority to AT01912573T priority patent/ATE429926T1/en
Publication of WO2001062799A2 publication Critical patent/WO2001062799A2/en
Publication of WO2001062799A3 publication Critical patent/WO2001062799A3/en
Anticipated expiration legal-status Critical
Priority to US10/229,394 priority patent/US20030050245A1/en
Priority to US11/433,628 priority patent/US20060270599A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides a proteinaceous molecule comprising a lysine and/or arginine residue and/or a functional equivalent thereof, capable of providing enhanced levels of plasmin in a mammalian through tPA mediated plasminogen activation for use as a pharmaceutical. The invention further provides use of a proteinaceous molecule according to the invention for the preparation of a medicament for the treatment of diseases related with angiogenesis and/or inflammatory disorders and/or conformational disorders and/or ageing. Furthermore the invention provides a proteinaceous molecule to suppress tumor growth, to regress established tumors, to degrade amyloid-β and to inhibit amyloid-β action. Additionally the invention provides a method for the treatment of a disease associated with or dependent on angiogenesis and/or associated with amyloid deposition comprising administering to a patient an effective amount of a proteinaceous molecule comprising a lysine and/or arginine residue and/or a functional equivalent thereof, capable of providing enhanced levels of plasmin in a mammalian through tPA mediated plasminogen activation.
PCT/NL2001/000155 2000-02-25 2001-02-26 Method for inhibiting angiogenesis using molecules that enhance plasmin activity Ceased WO2001062799A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP01912573A EP1257582B1 (en) 2000-02-25 2001-02-26 Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity
CA002400823A CA2400823A1 (en) 2000-02-25 2001-02-26 Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity
DE60138524T DE60138524D1 (en) 2000-02-25 2001-02-26 PROCESS FOR INHIBITING ANGIOGENESIS USING MOLECULES THAT INCREASE PLASMINATION OR EXTEND PLASMA INACTIVITY
AU41262/01A AU4126201A (en) 2000-02-25 2001-02-26 Inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity
AT01912573T ATE429926T1 (en) 2000-02-25 2001-02-26 METHOD FOR INHIBITING ANGIOGENESIS USING MOLECULES THAT INCREASE PLASMIN FORMATION OR PROLONG PLASMIN ACTIVITY
US10/229,394 US20030050245A1 (en) 2000-02-25 2002-08-26 Inhibiting angiogenesis molecules that enhance plasmin formation or prolong plasmin activity
US11/433,628 US20060270599A1 (en) 2000-02-25 2006-05-12 Inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00200664.1 2000-02-25
EP00200664A EP1130031A1 (en) 2000-02-25 2000-02-25 Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/229,394 Continuation US20030050245A1 (en) 2000-02-25 2002-08-26 Inhibiting angiogenesis molecules that enhance plasmin formation or prolong plasmin activity

Publications (2)

Publication Number Publication Date
WO2001062799A2 WO2001062799A2 (en) 2001-08-30
WO2001062799A3 true WO2001062799A3 (en) 2002-04-04

Family

ID=8171096

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2001/000155 Ceased WO2001062799A2 (en) 2000-02-25 2001-02-26 Method for inhibiting angiogenesis using molecules that enhance plasmin activity

Country Status (7)

Country Link
US (2) US20030050245A1 (en)
EP (2) EP1130031A1 (en)
AT (1) ATE429926T1 (en)
AU (1) AU4126201A (en)
CA (1) CA2400823A1 (en)
DE (1) DE60138524D1 (en)
WO (1) WO2001062799A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689753B1 (en) * 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
EP1820806A1 (en) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinity regions
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1380290A1 (en) 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
WO2004009773A2 (en) 2002-07-23 2004-01-29 Ludwig Institute For Cancer Research Methods and compositions for activating or inhibiting vegf-d and vegf-c
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
CA2615078A1 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Methods for determining the effect of a treatment on the cross-.beta. structure content of a protein; selection of treatments and uses thereof
US8114832B2 (en) 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
EP1906995A2 (en) * 2005-07-13 2008-04-09 Crossbeta Biosciences B.V. Adjuvation through cross- structure
CA2615028A1 (en) 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Cross-.beta. structure binding compounds
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
EP2058000A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Immunogenic compositions capable of activating T cells
EP2058001A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens
TW202342093A (en) * 2020-03-24 2023-11-01 大陸商深圳瑞健生命科學研究院有限公司 Method and drug for treating Alzheimer disease
KR20220156934A (en) * 2020-03-24 2022-11-28 탈렌젠 인터내셔널 리미티드 Methods and drugs for promoting degradation of misfolded proteins and their aggregates
CN115697385A (en) 2020-05-11 2023-02-03 泰伦基国际有限公司 Method and medicine for treating spinal muscular atrophy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014102A1 (en) * 1989-05-24 1990-11-29 Temple University Of The Commonwealth System Of Higher Education Thrombus-targeted complexes of plasminogen activator and fibrin fragments
EP0589181A2 (en) * 1992-07-30 1994-03-30 Yeda Research And Development Company, Ltd. Synthetic peptides derived from vitronectin and pharmaceutical compositions comprising them
US5981697A (en) * 1992-12-17 1999-11-09 Behringwerke Aktiengesellschaft Synthetic peptides, antibodies against them and their use
WO2000004052A2 (en) * 1998-07-16 2000-01-27 Adprotech Limited Soluble derivatives of anti-angiogenic peptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819923A1 (en) * 1988-06-11 1989-12-21 Behringwerke Ag FIBRINE (OGEN) DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
SE9101853D0 (en) * 1991-06-17 1991-06-17 Jonas Wadstroem IMPROVED TISSUE ASHESIVE
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
CA2188647A1 (en) * 1994-05-02 1995-11-09 Stewart Anthony Cederholm-Williams Recombinant fibrin chains, fibrin and fibrin-homologs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014102A1 (en) * 1989-05-24 1990-11-29 Temple University Of The Commonwealth System Of Higher Education Thrombus-targeted complexes of plasminogen activator and fibrin fragments
EP0589181A2 (en) * 1992-07-30 1994-03-30 Yeda Research And Development Company, Ltd. Synthetic peptides derived from vitronectin and pharmaceutical compositions comprising them
US5981697A (en) * 1992-12-17 1999-11-09 Behringwerke Aktiengesellschaft Synthetic peptides, antibodies against them and their use
WO2000004052A2 (en) * 1998-07-16 2000-01-27 Adprotech Limited Soluble derivatives of anti-angiogenic peptides

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BARENDSZ-JANSON ANNEMARIE F ET AL: "In vitro tumor angiogenesis assays: Plasminogen lysine binding site 1 inhibits in vitro tumor-induced angiogenesis.", JOURNAL OF VASCULAR RESEARCH, vol. 35, no. 2, March 1998 (1998-03-01), pages 109 - 114, XP000929510, ISSN: 1018-1172 *
GECHTMAN ZEEV ET AL: "Synthetic peptides derived from the sequence around the plasmin cleavage site in vitronectin: Use in mapping the PAI-1 binding site.", FEBS (FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES) LETTERS, vol. 315, no. 3, 1993, pages 293 - 297, XP002143617, ISSN: 0014-5793 *
KOST C ET AL: "Limited plasmin proteolysis of vitronectin. Characterization of the adhesion protein as morpho-regulatory and angiostatin-binding factor", EUROPEAN JOURNAL OF BIOCHEMISTRY,DE,BERLIN, vol. 236, no. 2, 1 March 1996 (1996-03-01), pages 682 - 688-688, XP002121364, ISSN: 0014-2956 *
MACHOVICH RAYMUND ET AL: "Denatured proteins as cofactors for plasminogen activation.", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 344, no. 2, 1997, pages 343 - 349, XP002175284, ISSN: 0003-9861 *
MACHOVICH RAYMUND ET AL: "Myosin as cofactor and substrate in fibrinolysis.", FEBS LETTERS, vol. 407, no. 1, 1997, pages 93 - 96, XP002175285, ISSN: 0014-5793 *

Also Published As

Publication number Publication date
CA2400823A1 (en) 2001-08-30
US20030050245A1 (en) 2003-03-13
EP1257582A2 (en) 2002-11-20
EP1130031A1 (en) 2001-09-05
ATE429926T1 (en) 2009-05-15
EP1257582B1 (en) 2009-04-29
WO2001062799A2 (en) 2001-08-30
AU4126201A (en) 2001-09-03
US20060270599A1 (en) 2006-11-30
DE60138524D1 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
WO2001062799A3 (en) Method for inhibiting angiogenesis using molecules that enhance plasmin activity
WO2008036682A3 (en) Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
WO2005117954A3 (en) Compositions and methods for treatment of neovascular diseases
HUP0301405A2 (en) Compositions containing therapeutically active components having enhanced solubility
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
GB0410266D0 (en) Treatment of apoptosis
DE60331537D1 (en) COMBINATIONS FOR THE TREATMENT OF MULTIPLE MYELOMA
WO2007029249A3 (en) Oligoribonucleotides and methods of use thereof for treatment of cardiovascular diseases
WO2004103274A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2006035434A3 (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
BR0316050A (en) Methods of treating, controlling or preventing specific cancer and disease associated with unwanted angiogenesis and reducing or preventing an adverse effect associated with the administration of a second active ingredient and with radiation therapy, hormone therapy, biological therapy, or immunotherapy in a patient. suffering from a specific cancer, pharmaceutical composition and kit
WO2005105213A3 (en) Indole and azaindole derivatives with antitumor action
WO2007049098A3 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
CY1112637T1 (en) ACTIVITIES FOR PREVENTING AND TREATING US DISEASES CONTAINING A PYRAZOLOPYRIMIDIN PRODUCT
WO2005046593A3 (en) Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
JP2004537500A5 (en)
EP1544214A4 (en) ANTI-APC NON-NEUTRALIZING ANTIBODIES
AU2001266289A1 (en) 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
WO2006083780A3 (en) Glucuronidated nebivolol
WO2009003694A3 (en) Method for treating diseases related to mitochondrial dysfunction
UA99094C2 (en) Method for the treatment of patients with autoantibody positive disease
WO2005094899A8 (en) Clusterin antisense therapy for treatment of cancer
IL194500A0 (en) Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2400823

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10229394

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001912573

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001912573

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP